New drug ARGX-124 put to the test in healthy people
NCT ID NCT07377396
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether ARGX-124 is safe in healthy adults aged 18 to 65. Researchers will also measure how the drug moves through the body and how the immune system reacts. About 104 participants will receive either the drug or a placebo, and the study lasts up to 23 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Altasciences
RECRUITINGMontreal, H3P 3P1, Canada
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug pass its first safety hurdle?
- Can a new drug play nice with common medicines? a trial investigates
- Could a new pill quiet chronic pain? early trial puts it to the test
- Brain waves under pressure: can light uncover the signature of mental work?
- Can acting as patients teach nurses to truly listen?
- Who decides for you? survey asks incarcerated older adults